Haw Par Corporation Limited

OTCPK:HAWP.Y Stock Report

Market Cap: US$1.6b

Haw Par Valuation

Is HAWP.Y undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HAWP.Y when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HAWP.Y ($28.64) is trading above our estimate of fair value ($17.88)

Significantly Below Fair Value: HAWP.Y is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HAWP.Y?

Key metric: As HAWP.Y is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for HAWP.Y. This is calculated by dividing HAWP.Y's market cap by their current earnings.
What is HAWP.Y's PE Ratio?
PE Ratio14.4x
EarningsS$148.32m
Market CapS$2.13b

Price to Earnings Ratio vs Peers

How does HAWP.Y's PE Ratio compare to its peers?

The above table shows the PE ratio for HAWP.Y vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average26.1x
INVA Innoviva
18.6xn/aUS$1.2b
SUPN Supernus Pharmaceuticals
33.4x36.2%US$2.0b
NDOI Endo
0.5xn/aUS$1.8b
LGND Ligand Pharmaceuticals
51.9x35.5%US$2.3b
HAWP.Y Haw Par
14.4xn/aUS$2.1b

Price-To-Earnings vs Peers: HAWP.Y is good value based on its Price-To-Earnings Ratio (14.4x) compared to the peer average (23.8x).

Price to Earnings Ratio vs Industry

How does HAWP.Y's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

9 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NDOI Endo
0.5xn/aUS$1.83b
PROC Procaps Group
2.9xn/aUS$143.29m
KPRX Kiora Pharmaceuticals
1.9x-40.4%US$9.96m
EDXC Endexx
0.9xn/aUS$6.28m
HAWP.Y 14.4xIndustry Avg. 19.3xNo. of Companies9PE01224364860+
9 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: HAWP.Y is good value based on its Price-To-Earnings Ratio (14.4x) compared to the US Pharmaceuticals industry average (26.7x).

Price to Earnings Ratio vs Fair Ratio

What is HAWP.Y's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HAWP.Y PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate HAWP.Y's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.9b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.59

7D

-1.3%

1Y

69.3%

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$31.19

7D

4.8%

1Y

22.3%

IQVIA Holdings

US$37.0b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.23

7D

5.2%

1Y

-4.6%